Li, Rui <br/><br/>
Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.  [electronic resource] 

 -  Molecular cancer therapeutics  Oct 2013 
 - 2200-12 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-8514 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-13-0095  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Apoptosis--drug effects<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cell Line, Tumor<br/>Drug Resistance, Neoplasm--drug effects<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Humans<br/>Mutation<br/>Niclosamide--administration & dosage<br/>Phosphorylation--drug effects<br/>Proto-Oncogene Proteins c-bcl-2--genetics<br/>Quinazolines--administration & dosage<br/>STAT3 Transcription Factor--biosynthesis<br/>Signal Transduction--drug effects<br/>Xenograft Model Antitumor Assays<br/>bcl-X Protein--biosynthesis